BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 17894058)

  • 1. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia.
    Johnson DA
    Br J Hosp Med; 1977 Jun; 17(6):546-58. PubMed ID: 18242
    [No Abstract]   [Full Text] [Related]  

  • 3. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions.
    Devito RA; Brink L; Sloan C; Jolliff F
    J Clin Psychiatry; 1978 Jan; 39(1):26-34. PubMed ID: 24614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.
    Liu PY; Wu PC; Chen CY; Chen YC
    Gen Hosp Psychiatry; 2011; 33(1):84.e5-7. PubMed ID: 21353143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison between the effectiveness of fluphenazine decanoate and oxyprothepin decanoate in schizophrenia (double-blind crossover study)].
    Balon R; Kabesh Ia; Papezhova G
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(1):116-8. PubMed ID: 6121437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with fluphenazine decanoate in the treatment of patients with long-standing chronic schizophrenia.
    Christodoulidis H; Frangos H
    Curr Ther Res Clin Exp; 1975 Jul; 18(1 pt 2):193-8. PubMed ID: 809234
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK; Wong KE; Tay WK; Gill RC
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].
    Woggon B; Dick P; Fleischhauer HJ; Gmür M; Gruber G; Angst J; Heimann H
    Int Pharmacopsychiatry; 1977; 12(4):193-209. PubMed ID: 22515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
    Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluphenazine decanoate causing atrioventricular block.
    Rao AV
    Indian Heart J; 1996; 48(6):713-4. PubMed ID: 9062027
    [No Abstract]   [Full Text] [Related]  

  • 14. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug monitoring at an Australia depot phenothiazine clinic.
    Marriott P; Hiep A
    J Clin Psychiatry; 1978 Mar; 39(3):206-12. PubMed ID: 580271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot fluphenazine: risk/benefit ratio.
    Glazer WM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose treatment strategies.
    Van Putten T; Marder SR
    J Clin Psychiatry; 1986 May; 47 Suppl():12-6. PubMed ID: 2871010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of depot neuroleptics: clinical experience in the United States.
    Kane JM
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing from oral to depot fluphenazine.
    Yadalam KG; Simpson GM
    J Clin Psychiatry; 1988 Sep; 49(9):346-8. PubMed ID: 3417620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)].
    Zhang YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Aug; 14(3):182-5. PubMed ID: 7333179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.